secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0001493152-25-003707
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies
--------------------------------------------------------------------------------

- GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.
- Phase 1 dose-escalation trial will enroll up to ~14 patients (7 cohorts) with r/r CD33+ AML and MDS.
- Initial clinical data from the study expected in 2025.
- Trial assesses safety, PK, PD, NK cell expansion, and clinical activity over up to 4 months of treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/0001493152-25-003707-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315225003707/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003707

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer